A randomized phase II study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer

BACKGROUND: Use of radiopharmaceutical may improve the survival time of patients with castrate-resistant prostate cancer and bone metastases. Whether androgen-deprivation therapy (ADT) combined with bone-targeted therapy provides clinical benefit for patients with advanced castrate-sensitive prostat...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Cancer
मुख्य लेखकों: Bilen, Mehmet Asim, Johnson, Marcella M., Mathew, Paul, Pagliaro, Lance C., Araujo, John C., Aparicio, Ana, Corn, Paul G., Tannir, Nizar M., Wong, Franklin C., Fisch, Michael J., Logothetis, Christopher, Tu, Shi-Ming
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: 2014
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC4270821/
https://ncbi.nlm.nih.gov/pubmed/25155428
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.28971
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन